Business
Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office
Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\nSAN FRANCISCO and TEL AVIV, ISRAEL, May 29, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the \"Company\" or \"Kalytera\") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering Kalytera’s novel compositions of cannabidiol (“CBD”) in combination with certain metabolites of the human microbiome as a potential treatment for ulcerative colitis, Crohn’s disease, inflammatory bowel disease (“IBD”), graft versus host disease (“GVHD”) and other GI tract inflammatory diseases.\n The patent application is based on recent novel findings from laboratory research conducted by Kalytera, including key findings demonstrating that CBD and certain metabolites of the human microbiome, when administered in combination, have an unexpected and superior effect upon improvement of gastrointestinal epithelial barrier function than does either such component administered separately.  Patent Claims Include: The pharmaceutical composition of CBD and a bacterial metabolite of tryptophan or butyric acid, as a highly effective treatment for gastrointestinal diseases or disorders characterized by damage to the gastrointestinal epithelial tight junctions and consequent abnormal intestinal permeability.The use of such pharmaceutical composition for improving gastrointestinal epithelial barrier function.The use of such pharmaceutical composition for treatment of ulcerative colitis, Crohn’s disease, IBD, acute or chronic GVHD, or any other acute or chronic gastro-intestinal inflammation. Kalytera’s ResearchKalytera operates a research laboratory focused on understanding and identifying the activity of CBD and other cannabinoids in combination with metabolites produced by the human microbiome.  The Significance of Kalytera’s FindingsBreakdown of the epithelial cell barrier lining the GI tract can lead to IBD and other intestinal diseases. In the most serious cases, bacteria are able to pass through the non-functioning barrier and enter the bloodstream, causing sepsis, a potentially life-threatening condition. Kalytera’s work has confirmed that CBD alone promotes direct repair of the damaged epithelial cell barrier. Kalytera’s work...